Edition:
United States

Express Scripts Holding Co (ESRX.O)

ESRX.O on Nasdaq

64.11USD
24 Mar 2017
Change (% chg)

$0.09 (+0.14%)
Prev Close
$64.02
Open
$64.00
Day's High
$64.35
Day's Low
$63.75
Volume
3,106,266
Avg. Vol
4,241,623
52-wk High
$80.02
52-wk Low
$63.22

Latest Key Developments (Source: Significant Developments)

Express Scripts reports Q4 GAAP EPS $2.34
Tuesday, 14 Feb 2017 04:22pm EST 

Express Scripts Holding Co : Express scripts announces 2016 fourth quarter and full year results . Q4 GAAP earnings per share $2.34 . Q4 earnings per share view $1.87 -- Thomson Reuters I/B/E/S . Reaffirms FY 2017 adjusted earnings per share view $6.82 to $7.02 . Q4 adjusted earnings per share $1.88 . Express scripts holding co says q4 adjusted claims of 354.9 million, down 6 pct, largely due to roll-off of coventry business . Express scripts holding reaffirms its 2017 adjusted earnings per diluted share guidance in range of $6.82 to $7.02 . Says expects total adjusted claims for Q1 of 2017 to be in range of 345 million to 355 million . Q4 revenue $24.86 billion versus $26.18 billion . Says adjusted earnings per diluted share for Q1 of 2017 is estimated to be in range of $1.30 to $1.34 .Q4 revenue view $26.31 billion -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding announces 2017 savings plan
Monday, 6 Feb 2017 06:00am EST 

Express Scripts Holding Co : Says in 2016, Express Scripts National Preferred Formulary saved plans $1.3 billion .Says Express Scripts National Preferred Formulary is projected to deliver additional $1.8 billion in savings in 2017.  Full Article

Express Scripts says conversation on drug pricing not going away
Wednesday, 14 Dec 2016 11:38am EST 

Express Scripts Holding Co - : Express Scripts says it expects fewer patent expirations in 2017 relative to 2016: conf call . Express Scripts says diabetes care value program will significantly impact anticipated increase in diabetes drug spend in 2017: conf call . Express Scripts is testing asthma remote monitoring solution that combines inhaler sensors, smartphone app, and monitoring from sos center: conf call . Express Scripts CEO says "it's so early but...i've not seen anything that causes me to be hugely concerned" in relation to incoming Trump administration . Express Scripts says has incorporated a "moderate level of inflation" for 2017, says unlikely inflation will represent a significant headwind . Express Scripts says "we've been disciplined with m&a, we've not announced anything, and it's not that we aren't engaged" : conf call . Express Scripts says expects to return the majority of its free cash flow to shareholders in 2017 via share repurchases in the open market: conf call . Express Scripts plans to achieve cost reductions in 2017 resulting in flat to slightly lower SG&A expense in 2017 versus 2016: conf call . Express Scripts says in 2016 it saw greater than 97.5 percent client retention: conf call . Express Scripts says in 2017, it expects to deliver $1.8 billion in client savings from national preferred formulary clients : conf call.  Full Article

Express Scripts Holding announces 2017 financial guidance
Wednesday, 14 Dec 2016 07:00am EST 

Express Scripts Holding Co : Sees total adjusted claims for year ending December 31, 2017 1,375 million to 1,425 million . Express Scripts Holding Company announces 2017 financial guidance . Reaffirms FY 2016 adjusted earnings per share view $6.36 to $6.42 . Sees FY 2017 adjusted earnings per share $6.82 to $7.02 . Sees FY 2016 earnings per share $5.28 to $5.34 . Sees cash flow from operations for year ending December 31, 2017 $4,700 million to $5,200 million . Updating 2016 total adjusted claims guidance from a range of 1,265 million to 1,280 million to a range of 1,400 million to 1,415 million . FY2016 earnings per share view $6.39, revenue view $101.66 billion -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $6.93 -- Thomson Reuters I/B/E/S . Revising methodology for reporting network claims for 2017 guidance, for reporting periods beginning with year ending Dec 31, 2016 .Revised methodology includes adjustment to reflect non-specialty network claims filled through 90-day network programs.  Full Article

Express Scripts chief medical officer says Mylan has a monopoly on the EpiPen
Thursday, 25 Aug 2016 04:03pm EDT 

: Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - "Mylan could lower the price today" . Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - Mylan has a monopoly on the epipen Further company coverage: [MYL.O ESRX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Express Scripts Q2 earnings per share $1.13
Monday, 25 Jul 2016 04:59pm EDT 

Express Scripts Holding Co : Says Q2 revenue $25.22 billion versus $25.45 billion . Sees Q3 total adjusted claims 311 million to 321 million . Year adjusted diluted eps guidance range; raises mid-point; provides 2016 third quarter guidance . Q2 earnings per share $1.13 . Q2 earnings per share view $1.57 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $6.33 to $6.43 . Q2 adjusted earnings per share $1.57 . Says Q2 adjusted claims of 315.3 million . Says narrows 2016 adjusted earnings per diluted share guidance to a range of $6.33 to $6.43 . Sees Q3 adjusted diluted earnings per share $1.72 to $1.76 .FY 2016 earnings per share view $6.35; q3 earnings per share view $1.72 -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding Co increases authorization for share repurchase program
Thursday, 3 Dec 2015 04:01pm EST 

Express Scripts Holding Co:Increases authorization for share repurchase program.Approved increase in number of shares that may be repurchased under share repurchase program by 60 million shares.  Full Article

Express Scripts Holding Co raises FY 2015 EPS guidance
Tuesday, 27 Oct 2015 04:01pm EDT 

Express Scripts Holding Co:Raised and narrowed its FY 2015 adjusted diluted earnings per share guidance from a range of $5.46 to $5.54 to a range of $5.51 to $5.55, which represents growth of 13% to 14% over FY 2014.FY 2015 EPS of $5.50 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

Judge dismisses two Express Scripts claims in Anthem drug pricing lawsuit

NEW YORK A federal judge has dismissed two of the six counterclaims that pharmacy benefits manager Express Scripts Holding Co raised in health insurer's Anthem Inc's $15 billion lawsuit claiming it charged too much for drugs.